{"transactions":[{"id":822842,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-01T21:19:31.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":105000,"derivative":{"exercise_price":2.49,"expiration_date":"2036-04-01","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001683168-26-002581","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826002581/ownership.xml","form_type":"4"}},{"id":1031885,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"ten_percent_owner":true}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":2,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}},{"id":64053,"kind":"person","name":"Brown Michael J","position":3,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":5,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}}],"security":"Common Stock","published_at":"2025-09-26T15:53:30.000Z","date":"2025-09-24","kind":"sale","planned":false,"acquired":false,"shares":550229,"price":63.6098,"value":34999956.6442,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc."}],"balance_after":272026,"source":{"system":"sec-edgar","filing":"0001437749-25-029925","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000143774925029925/rdgdoc.xml","form_type":"4"}},{"id":1177879,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"ten_percent_owner":true}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":2,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}},{"id":64053,"kind":"person","name":"Brown Michael J","position":3,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":5,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}}],"security":"Common Stock","published_at":"2025-04-04T19:27:32.000Z","date":"2025-04-02","kind":"sale","planned":false,"acquired":false,"shares":33334,"price":35,"value":1166690.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.86, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein."}],"balance_after":822255,"source":{"system":"sec-edgar","filing":"0001437749-25-011068","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000143774925011068/rdgdoc.xml","form_type":"4"}},{"id":1183404,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:43:25.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":110346,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter."}],"balance_after":110346,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":110346},"source":{"system":"sec-edgar","filing":"0001683168-25-002210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002210/ownership.xml","form_type":"4"}},{"id":1183403,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:43:25.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":51046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":51046,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":51046},"source":{"system":"sec-edgar","filing":"0001683168-25-002210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002210/ownership.xml","form_type":"4"}},{"id":2310690,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2022-04-01T21:28:29.000Z","date":"2022-03-31","kind":"exercise","acquired":false,"shares":1606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":88792,"derivative":{"underlying":"Common Stock","underlying_shares":1606},"source":{"system":"sec-edgar","filing":"0001654954-22-004490","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422004490/section16.xml","form_type":"4"}},{"id":2310689,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-01T21:28:29.000Z","date":"2022-03-31","kind":"tax_withholding","acquired":false,"shares":471,"price":2.55,"value":1201.05,"ownership":{"direct":true},"balance_after":22124.8,"source":{"system":"sec-edgar","filing":"0001654954-22-004490","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422004490/section16.xml","form_type":"4"}},{"id":2310688,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-01T21:28:29.000Z","date":"2022-03-31","kind":"exercise","acquired":true,"shares":1606,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":22595.8,"source":{"system":"sec-edgar","filing":"0001654954-22-004490","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422004490/section16.xml","form_type":"4"}},{"id":2411315,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-05T00:38:47.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":67251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025)"}],"balance_after":90398,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":67251},"source":{"system":"sec-edgar","filing":"0001654954-22-001174","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422001174/section16.xml","form_type":"4"}},{"id":2411314,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2022-02-05T00:38:47.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":88874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter."}],"balance_after":88874,"derivative":{"exercise_price":2.8,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":88874},"source":{"system":"sec-edgar","filing":"0001654954-22-001174","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422001174/section16.xml","form_type":"4"}},{"id":2447240,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-04T19:49:51.000Z","date":"2022-01-01","kind":"exercise","acquired":false,"shares":1937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":3874,"derivative":{"underlying":"Common Stock","underlying_shares":1937},"source":{"system":"sec-edgar","filing":"0001654954-22-000130","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000130/section16.xml","form_type":"4"}},{"id":2447239,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-04T19:49:51.000Z","date":"2022-01-01","kind":"tax_withholding","acquired":false,"shares":671,"price":3.21,"value":2153.91,"ownership":{"direct":true},"balance_after":20989.8,"source":{"system":"sec-edgar","filing":"0001654954-22-000130","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000130/section16.xml","form_type":"4"}},{"id":2447238,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-04T19:49:51.000Z","date":"2022-01-01","kind":"exercise","acquired":true,"shares":1937,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":21660.8,"source":{"system":"sec-edgar","filing":"0001654954-22-000130","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000130/section16.xml","form_type":"4"}},{"id":2447243,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-04T19:40:18.000Z","date":"2021-12-31","kind":"exercise","acquired":false,"shares":1606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":19273,"derivative":{"underlying":"Common Stock","underlying_shares":1606},"source":{"system":"sec-edgar","filing":"0001654954-22-000129","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000129/section16.xml","form_type":"4"}},{"id":2447242,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-04T19:40:18.000Z","date":"2021-12-31","kind":"tax_withholding","acquired":false,"shares":556,"price":3.21,"value":1784.76,"ownership":{"direct":true},"balance_after":19723.8,"source":{"system":"sec-edgar","filing":"0001654954-22-000129","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000129/section16.xml","form_type":"4"}},{"id":2447241,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-04T19:40:18.000Z","date":"2021-12-31","kind":"exercise","acquired":true,"shares":1606,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":20279.8,"source":{"system":"sec-edgar","filing":"0001654954-22-000129","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000129/section16.xml","form_type":"4"}},{"id":2553848,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2021-10-01T23:31:12.000Z","date":"2021-09-30","kind":"exercise","acquired":false,"shares":1606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":20879,"derivative":{"underlying":"Common Stock","underlying_shares":1606},"source":{"system":"sec-edgar","filing":"0001654954-21-010720","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421010720/section16.xml","form_type":"4"}},{"id":2553847,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-10-01T23:31:12.000Z","date":"2021-09-30","kind":"tax_withholding","acquired":false,"shares":471,"price":4.87,"value":2293.77,"ownership":{"direct":true},"balance_after":18673.8,"source":{"system":"sec-edgar","filing":"0001654954-21-010720","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421010720/section16.xml","form_type":"4"}},{"id":2553846,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-10-01T23:31:12.000Z","date":"2021-09-30","kind":"exercise","acquired":true,"shares":1606,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":19144.8,"source":{"system":"sec-edgar","filing":"0001654954-21-010720","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421010720/section16.xml","form_type":"4"}},{"id":2643547,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2021-07-02T21:11:27.000Z","date":"2021-06-30","kind":"exercise","acquired":false,"shares":3212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":22485,"derivative":{"underlying":"Common Stock","underlying_shares":3212},"source":{"system":"sec-edgar","filing":"0001654954-21-007595","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421007595/section16.xml","form_type":"4"}},{"id":2643546,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-07-02T21:11:27.000Z","date":"2021-06-30","kind":"tax_withholding","acquired":false,"shares":942,"price":5.89,"value":5548.38,"ownership":{"direct":true},"balance_after":17538.8,"source":{"system":"sec-edgar","filing":"0001654954-21-007595","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421007595/section16.xml","form_type":"4"}},{"id":2643545,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-07-02T21:11:27.000Z","date":"2021-06-30","kind":"exercise","acquired":true,"shares":3212,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":18480.8,"source":{"system":"sec-edgar","filing":"0001654954-21-007595","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421007595/section16.xml","form_type":"4"}},{"id":2859929,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":2,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":3,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":64053,"kind":"person","name":"Brown Michael J","position":5,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common stock","published_at":"2021-02-16T19:35:11.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":11929,"price":16.9,"value":201600.1,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on November 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $17.01, inclusive."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein."}],"balance_after":166667,"source":{"system":"sec-edgar","filing":"0001654954-21-001750","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000165495421001750/section16.xml","form_type":"4"}},{"id":2859928,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":2,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":3,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":64053,"kind":"person","name":"Brown Michael J","position":5,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common stock","published_at":"2021-02-16T19:35:11.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":16384,"price":16.44,"value":269352.96,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on November 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.77 to $16.76, inclusive."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein."}],"balance_after":178596,"source":{"system":"sec-edgar","filing":"0001654954-21-001750","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000165495421001750/section16.xml","form_type":"4"}},{"id":2859927,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":2,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":3,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":64053,"kind":"person","name":"Brown Michael J","position":5,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common stock","published_at":"2021-02-16T19:35:11.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":29996,"price":15.12,"value":453539.52,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on November 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.76 to $15.75, inclusive."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein."}],"balance_after":194980,"source":{"system":"sec-edgar","filing":"0001654954-21-001750","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000165495421001750/section16.xml","form_type":"4"}},{"id":2859926,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":2,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":3,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":64053,"kind":"person","name":"Brown Michael J","position":5,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common stock","published_at":"2021-02-16T19:35:11.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":24224,"price":14.09,"value":341316.16,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on November 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.66 to $14.54, inclusive."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein."}],"balance_after":224976,"source":{"system":"sec-edgar","filing":"0001654954-21-001750","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000165495421001750/section16.xml","form_type":"4"}},{"id":2859925,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":2,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":3,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":64053,"kind":"person","name":"Brown Michael J","position":5,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common stock","published_at":"2021-02-16T19:35:11.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":42467,"price":13.3,"value":564811.1,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on November 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.66 to $13.65, inclusive. The\nreporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein."}],"balance_after":249200,"source":{"system":"sec-edgar","filing":"0001654954-21-001750","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000165495421001750/section16.xml","form_type":"4"}},{"id":2891839,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2021-01-28T23:49:40.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":25697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2021 and 3/48ths each quarter-end thereafter (September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2021 and 3/48ths each quarter-end thereafter (September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024)"}],"balance_after":31508,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":25697},"source":{"system":"sec-edgar","filing":"0001654954-21-000911","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421000911/section16.xml","form_type":"4"}},{"id":2891838,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2021-01-28T23:49:40.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":36077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on June 30, 2021 and 1/48th monthly on the last day of each month thereafter."}],"balance_after":36077,"derivative":{"exercise_price":6.81,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":36077},"source":{"system":"sec-edgar","filing":"0001654954-21-000911","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421000911/section16.xml","form_type":"4"}},{"id":2918640,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2021-01-05T22:38:22.000Z","date":"2021-01-01","kind":"exercise","acquired":false,"shares":1937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":5811,"derivative":{"underlying":"Common Stock","underlying_shares":1937},"source":{"system":"sec-edgar","filing":"0001654954-21-000156","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421000156/section16.xml","form_type":"4"}},{"id":2918639,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-05T22:38:22.000Z","date":"2021-01-01","kind":"tax_withholding","acquired":false,"shares":671,"price":6.12,"value":4106.52,"ownership":{"direct":true},"balance_after":15268.8,"source":{"system":"sec-edgar","filing":"0001654954-21-000156","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421000156/section16.xml","form_type":"4"}},{"id":2918638,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-05T22:38:22.000Z","date":"2021-01-01","kind":"exercise","acquired":true,"shares":1937,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":15939.8,"source":{"system":"sec-edgar","filing":"0001654954-21-000156","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421000156/section16.xml","form_type":"4"}},{"id":3258722,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2020-02-21T01:55:43.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":32193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options vest 6/48ths on the 6-month anniversary of vesting commencement date of January 1, 2020, and 1/48th per month thereafter"}],"balance_after":32193,"derivative":{"exercise_price":14.35,"expiration_date":"2030-01-31","underlying":"Common Stock","underlying_shares":32193},"source":{"system":"sec-edgar","filing":"0001654954-20-001792","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495420001792/section16.xml","form_type":"4"}},{"id":3258721,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-21T01:55:43.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":7748,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024."}],"balance_after":7748,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7748},"source":{"system":"sec-edgar","filing":"0001654954-20-001792","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495420001792/section16.xml","form_type":"4"}},{"id":3334113,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":2,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Scientific Officer"}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":3,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Executive Officer"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true}},{"id":64053,"kind":"person","name":"Brown Michael J","position":5,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common stock","published_at":"2019-12-20T18:33:25.000Z","date":"2019-12-18","kind":"purchase","acquired":true,"shares":125000,"price":8,"value":1000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein."}],"balance_after":291667,"source":{"system":"sec-edgar","filing":"0001654954-19-014150","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000165495419014150/section16.xml","form_type":"4"}},{"id":3806386,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options","published_at":"2018-09-27T22:32:32.000Z","date":"2018-08-09","kind":"grant","acquired":true,"shares":134300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter."}],"balance_after":134300,"derivative":{"exercise_price":6,"exercise_date":"2019-04-01","expiration_date":"2028-08-08","underlying":"Common stock","underlying_shares":134300},"source":{"system":"sec-edgar","filing":"0001654954-18-010573","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495418010573/section16.xml","form_type":"4"}}]}